Drug Profile


Alternative Names: Escitalopram/aripiprazole; OPC-14597/escitalopram

Latest Information Update: 13 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Class Antidepressants; Antipsychotics; Benzofurans; Nitriles; Piperazines; Propylamines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 13 Aug 2013 No development reported - Phase-III for Major depressive disorder (treatment-experienced) in USA, Australia, Bulgaria, Croatia, Estonia, Finland, France, Germany, Hungary, India, Mexico, Romania, Slovakia, South Korea, Spain and Taiwan (PO)
  • 15 Jul 2011 Otsuka terminates four phase III trials in Major depressive disorder (NCT01111539, NCT01111552, NCT01111565, NCT01123707)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top